Clinical Remission After Therapeutic Apheresis in a Patient Suffering from Long Term Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Case Report.

Harald Burgard
Author Information
  1. Harald Burgard: Center for Toxopherese��, Private Practice, Wadgassen, Germany. ORCID

Abstract

Myalgic Encephalomyelitis/Chronic fatigue Syndrome (ME/CFS) is a debilitating multifactorial illness characterized by profound fatigue persisting for more than six months, post-exertional malaise, cognitive impairments, and a range of systemic symptoms. Until now, no accepted causal treatment regimens have been available; therapeutic options include different approaches, such as alleviation of symptoms and promotion of energy conservation. In this study, we report the case of a 49-year-old female presented to our center suffering from ME/CFS for more than 15 years, characterised by a strong energy loss and neurological and systemic symptoms; previous therapies remained unsuccessful. Therefore, we decided to perform double-filtration apheresis. After comprehensive laboratory evaluation, including investigation of persistent viral infections, the patient was treated eight times with double-filtration apheresis within a period of 2 years, which resulted in a remarkable sustained clinical remission and significant improvement in her quality of life. Therefore, we conclude that double-filtration apheresis could be an effective therapeutic tool for the treatment of ME/CFS.

Keywords

References

  1. BMC Med. 2011 Jul 28;9:91 [PMID: 21794183]
  2. Front Physiol. 2017 Feb 17;8:88 [PMID: 28261110]
  3. J Clin Med. 2020 Jul 30;9(8): [PMID: 32751659]
  4. Int J Mol Med. 2003 Aug;12(2):225-30 [PMID: 12851722]
  5. BMJ Open. 2018 Sep 4;8(9):e020817 [PMID: 30181183]
  6. JAMA. 2015 Mar 17;313(11):1101-2 [PMID: 25668027]
  7. Mol Psychiatry. 2023 Jul;28(7):2872-2877 [PMID: 37131073]
  8. Medicina (Kaunas). 2021 May 19;57(5): [PMID: 34069603]
  9. Science. 2024 Jan 19;383(6680):eadg7942 [PMID: 38236961]
  10. PLoS One. 2018 Mar 15;13(3):e0193672 [PMID: 29543914]
  11. Nat Rev Neurol. 2020 Nov;16(11):601-617 [PMID: 33005040]
  12. J Clin Med. 2021 Aug 19;10(16): [PMID: 34441971]
  13. Med Hypotheses. 2013 Sep;81(3):414-23 [PMID: 23790471]
  14. Heliyon. 2023 Apr 20;9(5):e15595 [PMID: 37131449]
  15. Pediatrics. 2009 Jul;124(1):189-93 [PMID: 19564299]
  16. Brain Behav Immun. 2016 Feb;52:32-39 [PMID: 26399744]
  17. BMJ. 2006 Sep 16;333(7568):575 [PMID: 16950834]

Word Cloud

Created with Highcharts 10.0.0ME/CFSdouble-filtrationapheresissymptomsMyalgicEncephalomyelitis/ChronicFatigueSyndromesystemictreatmenttherapeuticenergyyearsThereforedebilitatingmultifactorialillnesscharacterizedprofoundfatiguepersistingsixmonthspost-exertionalmalaisecognitiveimpairmentsrangenowacceptedcausalregimensavailableoptionsincludedifferentapproachesalleviationpromotionconservationstudyreportcase49-year-oldfemalepresentedcentersuffering15characterisedstronglossneurologicalprevioustherapiesremainedunsuccessfuldecidedperformcomprehensivelaboratoryevaluationincludinginvestigationpersistentviralinfectionspatienttreatedeighttimeswithinperiod2resultedremarkablesustainedclinicalremissionsignificantimprovementqualitylifeconcludeeffectivetoolClinicalRemissionTherapeuticApheresisPatientSufferingLongTerm:CaseReportautoantibodies

Similar Articles

Cited By

No available data.